ArticleEpilepsy currents2014
Cannabidiol: promise and pitfalls.
Article in Epilepsy currents, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06218056 (Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Use), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Use
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Long-Term Cognitive Outcomes After Sepsis: a Translational Systematic Review.Molecular neurobiology · 2019Pooled it
- The Current State of Unapproved Cannabidiol Product Use in Children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- The use of cannabidiol as adjunctive therapy in adult patients with drug-resistant epilepsy: a systematic review and meta-analysis.Therapeutic advances in neurological disorders · 2025Article
- A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders.Journal of cannabis research · 2024Review
- A Pilot Study on the Use of Low Doses of CBD to Control Seizures in Rare and Severe Forms of Drug-Resistant Epilepsy.Life (Basel, Switzerland) · 2022Article
- The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Considerations and Implications of Cannabidiol Use During Pregnancy.Current pain and headache reports · 2020Review
- Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals.British journal of pharmacology · 2020Review
- An Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine.Pain and therapy · 2019Review
- Oral Ingestion ofCannabis and cannabinoid research · 2018Article
- ΔJournal of psychiatry & neuroscience : JPN · 2017Article
- An Orally ActiveFrontiers in pharmacology · 2016Article
- Cannabinoids for pediatric epilepsy? Up in smoke or real science?Translational pediatrics · 2015Review
- E-Cigarettes: A Review of New Trends in Cannabis Use.International journal of environmental research and public health · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past few years, increasing public and political pressure has supported legalization of medical marijuana. One of the main thrusts in this effort has related to the treatment of refractory epilepsy-especially in children with Dravet syndrome-using cannabidiol (CBD). Despite initiatives in numerous states to at least legalize possession of CBD oil for treating epilepsy, little published evidence is available to prove or disprove the efficacy and safety of CBD in patients with epilepsy. This review highlights some of the basic science theory behind the use of CBD, summarizes published data on clinical use of CBD for epilepsy, and highlights issues related to the use of currently available CBD products. Cannabidiol is the major nonpsychoactive component of Cannabis sativa. Over the centuries, a number of medicinal preparations derived from C. sativa have been employed for a variety of disorders, including gout, rheumatism, malaria, pain, and fever. These preparations were widely employed as analgesics by Western medical practitioners in the 19(th) century (1). More recently, there is clinical evidence suggesting efficacy in HIV-associated neuropathic pain, as well as spasms associated with multiple sclerosis (1).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.